title: [New progression of translational research on colorectal cancer].
abstract: Precision medicine is becoming the goal of translational research on colorectal cancer. Accurate molecular subtyping contributes to better guidance of clinical practice. The current TNM staging system of colorectal cancer is inadequate in terms of guiding clinical practice, such as the underestimation of prognosis of with stage II( and III( colorectal cancer TNM staging, and identification of high-risk and low-risk patients with stage II( colorectal cancer. Researchers from Europe and US have proposed a number of molecular subtypings with clinicopathological phenotypes and molecular phenotypes, which has certain practical significance and is beneficial to the choice of treatment regimen and targeted drugs. But the current results of subtyping research require further validations by clinical large scale multi-center trials. Based on precision medicine, molecular subtyping gradually reveals its clinical significance and is optimized through combining genomics with various clinical phenotypes, indicating its guidance for clinical practice, which is the inevitable course of precision medicine accomplishment. In recent years, there have been many new advances in colorectal cancer liver metastasis treatment. The prognosis of colorectal cancer patients undergoing resection of liver metastasis lesion is similar to those with stage III(. Early recurrence within 6 months after translational treatment and resection occurred in about one third of the patients with initially unresectable liver metastasis, and the overall survival was poor. Thus, an evaluation system should be established in order to avoid the strong therapy and strive for better quality of life in some patients. Individualized treatment for colorectal cancer is emphasized increasingly. Body fluid (peripheral blood and urine) marker detection is a recent research hotspot, including serum protein(polypeptide), plasma miRNA, circulating tumor cells and circulating nucleic acid.
authors.affiliation: Cancer Institute of Zhejiang University, Key Laboratory of Cancer Prevention and Intervention (China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China. zhengshu@zju.edu.cn.
authors.forename: Shu
authors.initials: S
authors.lastname: Zheng
authors.forename: Weiting
authors.initials: W
authors.lastname: Ge
authors.forename: Jiekai
authors.initials: J
authors.lastname: Yu
authors.forename: Qi
authors.initials: Q
authors.lastname: Dong
authors.forename: Jianwei
authors.initials: J
authors.lastname: Wang
authors.forename: Lirong
authors.initials: L
authors.lastname: Chen
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood / Q000652:urine; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D057285:Precision Medicine; D011379:Prognosis; D011788:Quality of Life; D057170:Translational Research, Biomedical
chemical_list: D014408:Biomarkers, Tumor